BCIQ Profiles

Company Profile ReportTarget Profile Report

AbbVie starts Phase I for TRAIL-receptor agonist in cancer

Apogenix AG (Heidelberg, Germany) said partner AbbVie Inc. (NYSE:ABBV) began a Phase I trial to evaluate ABBV-621 (APG880) in 92

Read the full 201 word article

How to gain access

Continue reading with a
two-week free trial.